HIFU, immunotherapy, and chemo for ER+ HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with invasive breast cancer that has not spread to distant organs (like the liver or lungs).
- Your cancer is ER-positive and HER2-negative, and it is considered high-risk (grade 3, or PR less than 20%, or Ki67 of 20% or more).
- You are in good general health (able to do daily activities without major problems).
- You have not had prior treatment with immunotherapy drugs like Keytruda or Opdivo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
Hear when a new ER+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.